HANSOH PHARMA (HANSEN PHARMACEUTICALS) HAS ISSUED A COMPREHENSIVE FINANCIAL AND OPERATING PERFORMANCE REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023. HANSEN PHARMACEUTICALS HAS ESTABLISHED A LEADING POSITION IN THE MAJOR THERAPEUTIC AREAS OF THE CHINESE PHARMACEUTICAL MARKET, INCLUDING TUMORS, INFECTIONS, CENTRAL NERVOUS SYSTEM DISEASES AND METABOLIC DISEASES, THE REPORT SHOWS. A total of seven innovative drugs were approved for the market during the period, and all of them were included in the National Health Insurance Catalog. Six new products were approved for the market during the reporting period, with one innovative drug receiving approval for two indications; and 23 new applications and clinical trials for ten innovative drugs were approved. Sales revenue of innovative drugs and collaboration products amounted to approximately RMB686.5 billion...Show More

HANSOH PHARMA (HANSEN PHARMACEUTICALS) HAS ISSUED A COMPREHENSIVE FINANCIAL AND OPERATING PERFORMANCE REPORT FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023. HANSEN PHARMACEUTICALS HAS ESTABLISHED A LEADING POSITION IN THE MAJOR THERAPEUTIC AREAS OF THE CHINESE PHARMACEUTICAL MARKET, INCLUDING TUMORS, INFECTIONS, CENTRAL NERVOUS SYSTEM DISEASES AND METABOLIC DISEASES, THE REPORT SHOWS. A total of seven innovative drugs were approved for the market during the period, and all of them were included in the National Health Insurance Catalog. Six new products were approved for the market during the reporting period, with one innovative drug receiving approval for two indications; and 23 new applications and clinical trials for ten innovative drugs were approved. Sales revenue of innovative drugs and collaboration products amounted to approximately RMB686.5 billion, accounting for 67.9% of total revenue. The company remained the industry leader in financial performance with revenues of approximately RMB1010.4 billion and a profit of approximately RMB37.8 billion. Hanssen Pharmaceuticals' ESG rating was upgraded to AA in 2023 by MSCI and was named “Best Advancement Company in the Industry” by S&P Worldwide. The Board of Directors proposes to pay a final dividend of HK14.22 cents per share for the year ended 31 December 2023. IN ADDITION, THE COMPANY HAS COMMUNICATED WITH THE AUDIT COMMITTEE ON THE SCOPE OF THE AUDIT, TIMING, MAJOR AUDIT FINDINGS AND ANY SIGNIFICANT INTERNAL CONTROL DEFICIENCIES IDENTIFIED DURING THE AUDIT PERIOD, AND SUBMITTED TO THE AUDIT COMMITTEE A STATEMENT REGARDING COMPLIANCE WITH THE ETHICAL REQUIREMENTS OF INDEPENDENCE, AND COMMUNICATED ALL REASONABLY DEEMED REASONABLE Relationships and other matters that have an impact on independence, with appropriate safeguards in place. The audit partner is Ho Siu-feng at EY. Financial statements are prepared in accordance with the Hong Kong Financial Reporting Guidelines published by the Hong Kong Association of Accountants.